Duchenne Muscular Dystrophy Drugs Market
Duchenne Muscular Dystrophy Drugs Market Scope:
Industry Analysis, Market Size, Growth, Trends Till
2031
Request Sample Report
Duchenne Muscular Dystrophy Drugs Market Size and Growth
The Duchenne Muscular Dystrophy Drugs market is expected to experience significant growth due to increasing prevalence of the disease. The market size for these drugs is projected to reach $2.5 billion by 2023, driven by advancements in research and new drug approvals. Key players include Sarepta Therapeutics, PTC Therapeutics, and Wave Life Sciences.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Biogen
◍ Roche
◍ Daiichi Sankyo
◍ Pfizer
◍ Cumberland Pharmaceuticals
◍ Santhera Pharmaceuticals
◍ Taiho Pharmaceutical
◍ Teijin Pharma
◍ Akashi Therapeutics
◍ Sarepta Therapeutics
◍ BioMarin
◍ Fibrogen Inc
◍ Nobelpharma Co. Ltd
◍ Eloxx Pharmaceuticals
The competitive landscape of the Duchenne Muscular Dystrophy Drugs Market includes companies like Biogen, Roche, Daiichi Sankyo, Pfizer, Cumberland Pharmaceuticals, Santhera Pharmaceuticals, Taiho Pharmaceutical, Teijin Pharma, Akashi Therapeutics, Sarepta Therapeutics, BioMarin, Fibrogen Inc, Nobelpharma Co. Ltd, and Eloxx Pharmaceuticals. These companies play a crucial role in developing and commercializing drugs for Duchenne Muscular Dystrophy, thereby contributing to the growth of the market.
- Biogen: Sales revenue of $13.44 billion
- Roche: Sales revenue of $61.59 billion
- Pfizer: Sales revenue of $51.75 billion
Request Sample Report
Market Segmentation
By Application
Hospitals
Clinics
Others
Request Sample Report
By Product
Molecular-based Therapies
Steroid Therapy
Other
◍
◍
◍
◍
◍
◍
Market Growth
Request Sample Report
$ X Billion USD
THANK YOU Email : sales@reportprime.com USA : +1 507 500 7209 Website : https://www.reportprime.com/ Request Sample Report Contact US Our Clients